Answers are grounded in this paper and cite their sources.
The previous disease control interval should be considered in stratification schemes for future phase 2 testing of new agents for the treatment of neuroblastoma. For the optimal evaluation of new treatment strategies that incorporate cytostatic agents, study design and selection of endpoints must take into account the current patterns of recurrence or progression of neuroblastoma.
No takes yet. Share an insight, caveat, or question.
Santana et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: